Mabion SA 2019 AR2
The report highlights Mabion S.A.'s operations and financial position for the fiscal year 2019. The company focused on the development, manufacturing, and registration of its biosimilar drug MabionCD20, including submitting answers to the European Medicines Agency (EMA) and engaging with the US FDA. Mabion obtained GMP certificates for its Scientific and Industrial Complex in Konstantynów Łódzki for both active substance and medicinal product manufacturing. Additionally, the company secured a financing agreement with the European Investment Bank for up to EUR 30 million to support its R&D and investment projects.
Company: Mabion SA
Sector: Manufacturing
Country: Poland
Year: 2019
Type: AR2
Pages: 99
Back to company
Mabion SA
Directors' Report
The report highlights Mabion S.A.'s operations and financial position for the fiscal year 2019. The company focused on the development, manufacturing, and registration of its biosimilar drug MabionCD20, including submitting answers to the European Medicines Agency (EMA) and engaging with the US FDA. Mabion obtained GMP certificates for its Scientific and Industrial Complex in Konstantynów Łódzki for both active substance and medicinal product manufacturing. Additionally, the company secured a financing agreement with the European Investment Bank for up to EUR 30 million to support its R&D and investment projects.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees